Skip to content

US · ATRC · MEDICAL - INSTRUMENTS & SUPPLIES

AtriCure, Inc. (ATRC) intrinsic value and stock valuation

$55.39as of 2026-11-21 · Mkt cap 2.11B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AtriCure, Inc. DCF and intrinsic value

InvestorsCraft values ATRC with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ATRC’s statements →

AtriCure, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Mason, OH 45040 atricure.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$534.5M+20.9% 5y CAGRd
20112025
Net income
-$-11.45M
20112025
Free cash flow
$48.3M
20112025
Total equity
$491.9M+3.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$534.5M$465.3M$399.3M$330.4M$274.3M
Operating income-$-3.45M-$-40.01M-$-26.68M-$-42.67M$55.2M
Net income-$-11.45M-$-44.7M-$-30.44M-$-46.47M$50.2M
EPSd-$-239.79K-$-951.67K-$-657.31K-$-1.02M$1.09M
Operating cash flow$57.3M$12.2M$4.48M-$-22.14M-$-13.78M
Capital expenditure-$-9.05M-$-23.46M-$-42M-$-16.88M-$-9.75M
Free cash flow$48.3M-$-11.26M-$-37.51M-$-39.02M-$-23.53M
Total assets$654.2M$609.3M$613.9M$585.5M$615.3M
Total debt$88M$76.5M$74.5M$74.6M$75.7M
Net debt-$-79.41M-$-46.19M-$-9.82M$16.5M$32M
Total equity$491.9M$461M$466.2M$456.8M$483.8M
Cash and short-term investments$167.4M$122.7M$137.3M$121.1M$119.1M
Income statement
20252024202320222021
Revenue$534.5M$465.3M$399.3M$330.4M$274.3M
Cost of revenue$136.8M$117.8M$98.9M$84.4M$68.5M
Gross profit$397.7M$347.5M$300.4M$245.9M$205.9M
Research and development expenses$90.2M$96.2M$73.9M$57.3M$48.5M
Selling, general and administrative expenses$311M$291.4M$253.1M$231.3M$204.7M
Other expenses$0.00$0.00$0.00$0.00-$-102.5M
Operating expenses$401.2M$387.5M$327.1M$288.6M$150.7M
Cost and expenses$538M$505.3M$425.9M$373.1M$219.1M
Interest income$4.48M$4.43M$3.79M$1.99M$470K
Interest expense$5.88M$6.41M$6.92M$4.99M$4.92M
Depreciation and amortization$20.5M$18.7M$14.8M$11.7M$10.4M
Ebitda$16.3M-$-18.53M-$-8.11M-$-29.5M$65.8M
Operating income-$-3.45M-$-40.01M-$-26.68M-$-42.67M$55.2M
Total other income/expenses, net-$-6.72M-$-3.66M-$-3.16M-$-3.53M-$-4.82M
Income before tax-$-10.16M-$-43.67M-$-29.85M-$-46.2M$50.4M
Income tax expense$1.28M$1.02M$590K$270K$190K
Net income-$-11.45M-$-44.7M-$-30.44M-$-46.47M$50.2M
Weighted average shares outstanding$47.8M$47M$46.3M$45.7M$45.1M
Weighted average diluted shares outstanding$47.8M$47M$46.3M$45.7M$46M
Balance sheet
20252024202320222021
Cash and short-term investments$167.4M$122.7M$137.3M$121.1M$119.1M
Net receivables$66.7M$60.3M$52.5M$42.7M$33M
Inventory$78.5M$75.3M$67.9M$45.9M$39M
Total current assets$322.5M$267.8M$266.3M$215.2M$196.1M
Property, plant and equipment, net$46M$47.4M$46.8M$42.6M$36.2M
Goodwill and intangible assets$282.8M$291.3M$298.8M$274.1M$277.8M
Long-term investments$0.00$0.00$0.00$51.5M$104.3M
Total non-current assets$331.7M$341.5M$347.7M$370.2M$419.2M
Total assets$654.2M$609.3M$613.9M$585.5M$615.3M
Accounts payable$78.4M$25M$27.4M$19.9M$18.6M
Short-term debt$3.12M$2.81M$2.53M$5.47M$1.76M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$81.5M$73.4M$74.6M$58.4M$56.5M
Long-term debt$84.9M$73.7M$72M$69.1M$73.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$80.7M$74.9M$73.2M$70.3M$75.1M
Capital lease obligations$11.5M$11.9M$11.4M$14.4M$15.9M
Total liabilities$162.2M$148.4M$147.8M$128.7M$131.6M
Common stock$50K$50K$50K$50K$50K
Retained earnings-$-413.2M-$-401.75M-$-357.06M-$-326.62M-$-280.15M
Accumulated other comprehensive income (loss)$570K-$-1.03M-$-990K-$-4.1M-$-950K
Total equity$491.9M$461M$466.2M$456.8M$483.8M
Total investments$0.00$0.00$53M$114.5M$179.8M
Total debt$88M$76.5M$74.5M$74.6M$75.7M
Net debt-$-79.41M-$-46.19M-$-9.82M$16.5M$32M
Cash flow statement
20252024202320222021
Net income-$-11.45M-$-44.7M-$-30.44M-$-46.47M$50.2M
Depreciation and amortization$20.5M$18.7M$14.8M$11.7M$10.4M
Stock-based compensation$44.7M$40.4M$35.7M$28.8M$28.1M
Change in working capital-$-4.29M-$-18.36M-$-18.24M-$-18.88M-$-4.85M
Accounts receivable-$-5.61M-$-8.3M-$-9.87M-$-8.99M-$-10.09M
Inventory-$-2.26M-$-7.74M-$-21.83M-$-7.3M-$-4.27M
Accounts payable-$-960K-$-1.53M$6.18M$2.68M$4.71M
Net cash provided by operating activities$57.3M$12.2M$4.48M-$-22.14M-$-13.78M
Investments in property, plant and equipment-$-9.05M-$-11.46M-$-12M-$-16.88M-$-9.75M
Acquisitions, net$0.00$0.00$0.00-$-44.01M-$-33.26M
Net cash used for investing activities-$-14.55M$30.2M$21.8M$44M$23.5M
Common stock issued$7.29M$0.00$0.00$0.00$0.00
Common stock repurchased-$-11.16M-$-6.95M-$-6.56M-$-12.2M-$-18.01M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.18M-$-3.6M-$-30K-$-7.06M-$-7.64M
Net change in cash$44.7M$38.4M$26.2M$14.5M$1.71M
Cash at end of period$167.4M$122.7M$84.3M$58.1M$43.7M
Operating cash flow$57.3M$12.2M$4.48M-$-22.14M-$-13.78M
Capital expenditure-$-9.05M-$-23.46M-$-42M-$-16.88M-$-9.75M
Free cash flow$48.3M-$-11.26M-$-37.51M-$-39.02M-$-23.53M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AtriCure, Inc.

        AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

        CEO
        Michael H. Carrel
        Employees
        1.35K
        Beta
        1.25

        Explore

        Frequently asked questions

        What is the intrinsic value of AtriCure, Inc. (ATRC)?

        AtriCure, Inc. (ATRC) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ATRC undervalued?

        ATRC trades at a price of $55.39 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.